Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer

CF Singer; M Filipits; S Jahn; L Abete; R Jakesz; Richard Greil; T Bauernhofer; W Kwasny; M Seifert; F Fitzal; M Schmitt; F Moinfar; M Gnant

doi:10.1158/1538-7445.SABCS15-P2-08-21

Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer

CF Singer, M Filipits, S Jahn, L Abete, R Jakesz, Richard Greil, T Bauernhofer, W Kwasny, M Seifert, F Fitzal, M Schmitt, F Moinfar, M Gnant

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Journal	CANCER RESEARCH
Volume	76
DOIs	https://doi.org/10.1158/1538-7445.SABCS15-P2-08-21
Publication status	Published - 2016
Event	38th Annual CTRC-AACR San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 8 Dec 2015 → 12 Dec 2015

Access to Document

10.1158/1538-7445.SABCS15-P2-08-21

Cite this

Singer, CF., Filipits, M., Jahn, S., Abete, L., Jakesz, R., Greil, R., Bauernhofer, T., Kwasny, W., Seifert, M., Fitzal, F., Schmitt, M., Moinfar, F., & Gnant, M. (2016). Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. CANCER RESEARCH , 76. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-21

Singer, CF ; Filipits, M ; Jahn, S et al. / Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. In: CANCER RESEARCH 2016 ; Vol. 76.

@article{5279cc4705fc4360a25321217755fe6f,

title = "Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer",

author = "CF Singer and M Filipits and S Jahn and L Abete and R Jakesz and Richard Greil and T Bauernhofer and W Kwasny and M Seifert and F Fitzal and M Schmitt and F Moinfar and M Gnant",

year = "2016",

doi = "10.1158/1538-7445.SABCS15-P2-08-21",

language = "English",

volume = "76",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

note = "38th Annual CTRC-AACR San Antonio Breast Cancer Symposium ; Conference date: 08-12-2015 Through 12-12-2015",

}

Singer, CF, Filipits, M, Jahn, S, Abete, L, Jakesz, R, Greil, R, Bauernhofer, T, Kwasny, W, Seifert, M, Fitzal, F, Schmitt, M, Moinfar, F & Gnant, M 2016, 'Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer', CANCER RESEARCH , vol. 76. https://doi.org/10.1158/1538-7445.SABCS15-P2-08-21

Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. / Singer, CF; Filipits, M; Jahn, S et al.
In: CANCER RESEARCH , Vol. 76, 2016.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer

AU - Singer, CF

AU - Filipits, M

AU - Jahn, S

AU - Abete, L

AU - Jakesz, R

AU - Greil, Richard

AU - Bauernhofer, T

AU - Kwasny, W

AU - Seifert, M

AU - Fitzal, F

AU - Schmitt, M

AU - Moinfar, F

AU - Gnant, M

PY - 2016

Y1 - 2016

U2 - 10.1158/1538-7445.SABCS15-P2-08-21

DO - 10.1158/1538-7445.SABCS15-P2-08-21

M3 - Abstract (Journal)

SN - 0008-5472

VL - 76

JO - CANCER RESEARCH

JF - CANCER RESEARCH

T2 - 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium

Y2 - 8 December 2015 through 12 December 2015

ER -

Singer CF, Filipits M, Jahn S, Abete L, Jakesz R, Greil R et al. Stromel co-expression of urokinase-type plasminogen activator (uPA) and plasminogen activator Inhibitor (PAI-1) protein by IHC predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer. CANCER RESEARCH . 2016;76. doi: 10.1158/1538-7445.SABCS15-P2-08-21